Evidence map›Paper›PMID 36262394›Full record

ArticleACS medicinal chemistry letters2022

Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.

Yosuke Ota, Yukihiro Itoh, Takashi Kurohara, Ritesh Singh, Elghareeb E Elboray, Chenliang Hu, Farzad Zamani, Anirban Mukherjee, Yuri Takada, Yasunobu Yamashita and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 3 countries.

Yosuke OtaGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.
Yukihiro ItohGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.ORCID https://orcid.org/0000-0002-3410-2924
Takashi KuroharaGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.ORCID https://orcid.org/0000-0003-4228-3478
Ritesh SinghGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.
Elghareeb E ElborayGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.
Chenliang HuSANKEN, Osaka University, Ibaraki, Osaka 567-0047, Japan.
Farzad ZamaniSANKEN, Osaka University, Ibaraki, Osaka 567-0047, Japan.
Anirban MukherjeeSANKEN, Osaka University, Ibaraki, Osaka 567-0047, Japan.
Yuri TakadaSANKEN, Osaka University, Ibaraki, Osaka 567-0047, Japan.ORCID https://orcid.org/0000-0002-7955-6567
Yasunobu YamashitaSANKEN, Osaka University, Ibaraki, Osaka 567-0047, Japan.ORCID https://orcid.org/0000-0001-5078-5940
Mie MoritaGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Mano HorinakaGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Yoshihiro SowaGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Mitsuharu MasudaGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Toshiyuki SakaiGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Takayoshi SuzukiGraduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.ORCID https://orcid.org/0000-0003-2439-879X
Kyoto Prefectural University of Medicine · JPThe University of Osaka · JPSouth Valley University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anticancer drug delivery by small molecules offers a number of advantages over conventional macromolecular drug delivery systems. We previously developed phenylcyclopropylamine (PCPA)-drug conjugates (PDCs) as small-molecule-based drug delivery vehicles for targeting lysine-specific demethylase 1 (LSD1)-overexpressing cancers. In this study, we applied this PDC strategy to the HDAC-inhibitory anticancer agent vorinostat. Among three synthesized PCPA or arylcyclopropylamine (ACPA)-vorinostat conjugates

Identifiers

PMID36262394
PMCPMC9575174
OpenAlexW4295631384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.